These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 33781856)

  • 1. Identification of harmine and β-carboline analogs from a high-throughput screen of an approved drug collection; profiling as differential inhibitors of DYRK1A and monoamine oxidase A and for in vitro and in vivo anti-cancer studies.
    Tarpley M; Oladapo HO; Strepay D; Caligan TB; Chdid L; Shehata H; Roques JR; Thomas R; Laudeman CP; Onyenwoke RU; Darr DB; Williams KP
    Eur J Pharm Sci; 2021 Jul; 162():105821. PubMed ID: 33781856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How to Separate Kinase Inhibition from Undesired Monoamine Oxidase A Inhibition-The Development of the DYRK1A Inhibitor AnnH75 from the Alkaloid Harmine.
    Wurzlbauer A; Rüben K; Gürdal E; Chaikuad A; Knapp S; Sippl W; Becker W; Bracher F
    Molecules; 2020 Dec; 25(24):. PubMed ID: 33339338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Data supporting a pilot high-throughput screen of a drug library for identification of DYRK1A inhibitors and high-content imaging analysis of identified harmine analogs.
    Tarpley M; Oladapo H; Caligan TB; Onyenwoke RU; Williams KP
    Data Brief; 2021 Aug; 37():107189. PubMed ID: 34141844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-Based Design and Synthesis of Harmine Derivatives with Different Selectivity Profiles in Kinase versus Monoamine Oxidase Inhibition.
    Bálint B; Wéber C; Cruzalegui F; Burbridge M; Kotschy A
    ChemMedChem; 2017 Jun; 12(12):932-939. PubMed ID: 28264138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and Biological Validation of a Harmine-Based, Central Nervous System (CNS)-Avoidant, Selective, Human β-Cell Regenerative Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase A (DYRK1A) Inhibitor.
    Kumar K; Wang P; Wilson J; Zlatanic V; Berrouet C; Khamrui S; Secor C; Swartz EA; Lazarus M; Sanchez R; Stewart AF; Garcia-Ocana A; DeVita RJ
    J Med Chem; 2020 Mar; 63(6):2986-3003. PubMed ID: 32003560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selectivity Profiling and Biological Activity of Novel β-Carbolines as Potent and Selective DYRK1 Kinase Inhibitors.
    Rüben K; Wurzlbauer A; Walte A; Sippl W; Bracher F; Becker W
    PLoS One; 2015; 10(7):e0132453. PubMed ID: 26192590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replication.
    Wang P; Alvarez-Perez JC; Felsenfeld DP; Liu H; Sivendran S; Bender A; Kumar A; Sanchez R; Scott DK; Garcia-Ocaña A; Stewart AF
    Nat Med; 2015 Apr; 21(4):383-8. PubMed ID: 25751815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rational Design and Identification of Harmine-Inspired, N-Heterocyclic DYRK1A Inhibitors Employing a Functional Genomic In Vivo Drosophila Model System.
    Huizar FJ; Hill HM; Bacher EP; Eckert KE; Gulotty EM; Rodriguez KX; Tucker ZD; Banerjee M; Liu H; Wiest O; Zartman J; Ashfeld BL
    ChemMedChem; 2022 Feb; 17(4):e202100512. PubMed ID: 34994084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isoform selectivity of harmine-conjugated 1,2,3-triazoles against human monoamine oxidase.
    Haider S; Alhusban M; Chaurasiya ND; Tekwani BL; Chittiboyina AG; Khan IA
    Future Med Chem; 2018 Jun; 10(12):1435-1448. PubMed ID: 29788780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
    Liu W; Liu X; Tian L; Gao Y; Liu W; Chen H; Jiang X; Xu Z; Ding H; Zhao Q
    Eur J Med Chem; 2021 Oct; 222():113554. PubMed ID: 34098466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human β-Cell Proliferation.
    Kumar K; Wang P; Sanchez R; Swartz EA; Stewart AF; DeVita RJ
    J Med Chem; 2018 Sep; 61(17):7687-7699. PubMed ID: 30059217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation.
    Göckler N; Jofre G; Papadopoulos C; Soppa U; Tejedor FJ; Becker W
    FEBS J; 2009 Nov; 276(21):6324-37. PubMed ID: 19796173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. β-carboline compounds, including harmine, inhibit DYRK1A and tau phosphorylation at multiple Alzheimer's disease-related sites.
    Frost D; Meechoovet B; Wang T; Gately S; Giorgetti M; Shcherbakova I; Dunckley T
    PLoS One; 2011 May; 6(5):e19264. PubMed ID: 21573099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Harmine is an ATP-competitive inhibitor for dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A).
    Adayev T; Wegiel J; Hwang YW
    Arch Biochem Biophys; 2011 Mar; 507(2):212-8. PubMed ID: 21185805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploiting the repertoire of CK2 inhibitors to target DYRK and PIM kinases.
    Cozza G; Sarno S; Ruzzene M; Girardi C; Orzeszko A; Kazimierczuk Z; Zagotto G; Bonaiuto E; Di Paolo ML; Pinna LA
    Biochim Biophys Acta; 2013 Jul; 1834(7):1402-9. PubMed ID: 23360763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The small molecule harmine regulates NFATc1 and Id2 expression in osteoclast progenitor cells.
    Egusa H; Doi M; Saeki M; Fukuyasu S; Akashi Y; Yokota Y; Yatani H; Kamisaki Y
    Bone; 2011 Aug; 49(2):264-74. PubMed ID: 21504804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined Inhibition of DYRK1A, SMAD, and Trithorax Pathways Synergizes to Induce Robust Replication in Adult Human Beta Cells.
    Wang P; Karakose E; Liu H; Swartz E; Ackeifi C; Zlatanic V; Wilson J; González BJ; Bender A; Takane KK; Ye L; Harb G; Pagliuca F; Homann D; Egli D; Argmann C; Scott DK; Garcia-Ocaña A; Stewart AF
    Cell Metab; 2019 Mar; 29(3):638-652.e5. PubMed ID: 30581122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel trisubstituted harmine derivatives with original in vitro anticancer activity.
    Frédérick R; Bruyère C; Vancraeynest C; Reniers J; Meinguet C; Pochet L; Backlund A; Masereel B; Kiss R; Wouters J
    J Med Chem; 2012 Jul; 55(14):6489-501. PubMed ID: 22770529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A natural compound harmine decreases melanin synthesis through regulation of the DYRK1A/NFATC3 pathway.
    Park CH; Kim G; Lee Y; Kim H; Song MJ; Lee DH; Chung JH
    J Dermatol Sci; 2021 Jul; 103(1):16-24. PubMed ID: 34030962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. beta-Carboline alkaloids in Peganum harmala and inhibition of human monoamine oxidase (MAO).
    Herraiz T; González D; Ancín-Azpilicueta C; Arán VJ; Guillén H
    Food Chem Toxicol; 2010 Mar; 48(3):839-45. PubMed ID: 20036304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.